BIONOMOUS raises CHF 1.3 million Seed funding in a round led by Nivalis Group.
Summary
The closing of this Seed funding round allows Bionomous to accelerate the testing phase, to develop a certified product ready-for-market, and to prepare for industrialization. Thanks to their support we were able to start the testing phase of our technology with end-users and make the first sales, which has been a key point in the closing of this Seed Round.Moreover, Venture Kick gave us the guidance, advice and tools needed to set out the principles of a company, to deal with a growing team and to build a strong network, which has been of great importance during the search for funding.When, and what, was your inspiration to found Bionmous?Our inspiration to found Bionomous was to help researchers by providing them tools to facilitate and accelerate their work.What is your advice for the potential biotech entrepreneurs launching companies in Switzerland today?Pitch your project to as many events as possible, even if you are bored by it, because you will only increase your chance to meet the right partner/investor that will like your project and team. Its eggs are particularly suited for research in the Life Sciences industry, to find new treatments, perform toxicology tests or better understand the biology and genetics of living organisms. Frank Bonnet Bionomous CEO & co-founder explains: Our team has demonstrated its capacity to develop products tailored to the specific needs of our customers. Thanks to this investment round, our team can explore the possibilities to apply our technology to other segments and study new opportunities to diversify our product lines.We interviewed Ana to know more about her entrepreneurial path.